Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of $11.37 million. The enterprise value is $18.52 million.
Important Dates
The next estimated earnings date is Thursday, November 20, 2025, before market open.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evogene has 8.72 million shares outstanding. The number of shares has increased by 32.03% in one year.
| Current Share Class | 8.72M |
| Shares Outstanding | 8.72M |
| Shares Change (YoY) | +32.03% |
| Shares Change (QoQ) | +6.29% |
| Owned by Insiders (%) | 0.99% |
| Owned by Institutions (%) | 1.85% |
| Float | 8.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.20 |
| Forward PS | 2.32 |
| PB Ratio | 0.92 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.96 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.21.
| Current Ratio | 1.89 |
| Quick Ratio | 0.86 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.80 |
Financial Efficiency
Return on equity (ROE) is -89.34% and return on invested capital (ROIC) is -67.78%.
| Return on Equity (ROE) | -89.34% |
| Return on Assets (ROA) | -32.39% |
| Return on Invested Capital (ROIC) | -67.78% |
| Return on Capital Employed (ROCE) | -103.59% |
| Revenue Per Employee | $80,718 |
| Profits Per Employee | -$121,821 |
| Employee Count | 117 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 2.68 |
Taxes
In the past 12 months, Evogene has paid $9,000 in taxes.
| Income Tax | 9,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.22% in the last 52 weeks. The beta is 1.43, so Evogene's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | -46.22% |
| 50-Day Moving Average | 1.25 |
| 200-Day Moving Average | 1.31 |
| Relative Strength Index (RSI) | 51.53 |
| Average Volume (20 Days) | 152,430 |
Short Selling Information
| Short Interest | 98,150 |
| Short Previous Month | 71,315 |
| Short % of Shares Out | 1.13% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.75 |
Income Statement
In the last 12 months, Evogene had revenue of $9.44 million and -$14.25 million in losses. Loss per share was -$2.14.
| Revenue | 9.44M |
| Gross Profit | 5.75M |
| Operating Income | -19.40M |
| Pretax Income | -14.43M |
| Net Income | -14.25M |
| EBITDA | -17.83M |
| EBIT | -19.40M |
| Loss Per Share | -$2.14 |
Full Income StatementBalance Sheet
The company has $11.69 million in cash and $2.66 million in debt, giving a net cash position of $9.03 million or $1.04 per share.
| Cash & Cash Equivalents | 11.69M |
| Total Debt | 2.66M |
| Net Cash | 9.03M |
| Net Cash Per Share | $1.04 |
| Equity (Book Value) | 12.38M |
| Book Value Per Share | -0.41 |
| Working Capital | 13.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.62 million and capital expenditures -$583,000, giving a free cash flow of -$18.20 million.
| Operating Cash Flow | -17.62M |
| Capital Expenditures | -583,000 |
| Free Cash Flow | -18.20M |
| FCF Per Share | -$2.09 |
Full Cash Flow StatementMargins
Gross margin is 60.93%, with operating and profit margins of -205.46% and -150.92%.
| Gross Margin | 60.93% |
| Operating Margin | -205.46% |
| Pretax Margin | -152.75% |
| Profit Margin | -150.92% |
| EBITDA Margin | -188.78% |
| EBIT Margin | -205.46% |
| FCF Margin | n/a |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.03% |
| Shareholder Yield | n/a |
| Earnings Yield | -125.34% |
| FCF Yield | -160.06% |
Analyst Forecast
The average price target for Evogene is $3.50, which is 173.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.50 |
| Price Target Difference | 173.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 25, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Evogene has an Altman Z-Score of -12.37 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.37 |
| Piotroski F-Score | 2 |
